NCT06513221View on ClinicalTrials.gov

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 12, 2027

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Chemotherapy, Bevacizumab, Adebrelimab

Adebrelimab: 1200mg，q3w Bevacizumab: 7.5mg/kg，q3w Fruquintinib: 4mg po d1\~d14, q3w Chemotherapy: XELOX/mXELIRI: conventional dose

All Listed Sponsors

lead

Fudan University

OTHER

NCT06513221 - A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | Biotech Hunter | Biotech Hunter